Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Earnings Call

BioStem Technologies Earnings Call: Key Takeaways

BioStem is undergoing a high-stakes transition, prioritizing a $10-$12 million cost reduction and in-house manufacturing to offset significant Q3 losses and a dwindling cash position.

Full earnings call on the Alfa Finder USA YouTube channel · Open on YouTube ↗
Highlights
Revenue GrowthHospital revenue $6.8M (up 2% seq); Physician office $810k (down from $1.1M).
Mgmt ConfidenceHigh conviction shown by CEO/COO $1M option exercise and salary-to-stock conversion.
Demand VisibilityStrongest hospital sales months in July/September; August impacted by systems transition.
Margin TrendsGross margin fell to 56% from 61%; targeting 10-15 point improvement.
Op. LeveragePlan to reduce annual cash operating expenses by $10M to $12M.
Pricing PowerPressure from higher transfer pricing under BioTissue supply agreement through 2026.
Vol vs PriceGrowth driven by deepening utilization; accounts buying 3+ lines rose 40%.
Segment GrowthHospital channel is primary focus; physician office contributions expected to be minimal.
New ClientsVendahy added to two largest U.S. GPO agreements in September.
Capex & Debt$40M equity facility; $3M private placement; evaluating receivable-based credit facility.
RegulatoryIn-house production start H1 2027 subject to process validation and regulatory requirements.
CommentaryStrategic shift from investment phase to 'disciplined expense management' and profitability.
New LaunchesCatalyze 510k clearance received; VLU study top-line results expected early December.

Growth

Hospital revenue grew 2% sequentially to $6.8M; total revenue fell to $7.6M from $7.9M.

Outlook

Raised FY2026 revenue floor to $28M-$29M; targeting 70% gross margins by FY2027.

Risks

Management pivoted on specific structural vs. non-recurring cost-saving breakdowns, citing the plan is still being finalized.

Source

The company's earnings call, NASDAQ: BSEM, and its 8-K filed with the SEC. Summary written with AI assistance from the call.

Read the 8-K ↗

BioStem Technologies, Inc.: key numbers

Share price
$0.9601Close, Nov 16
Market cap
$18.4M
Shares outstanding
19.18MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from BioStem Technologies, Inc.

All →
4:32 PM ET 10-Q
Financial Results ▶ Call

BioStem Technologies Q3 2026 Results: Net Loss of $11.4M

BioStem Technologies reported a significant decline in revenue to $21.7 million for the nine months ended September 30, 2026, compared to $37.4 million in the prior year, resulting in a net loss from operations of $27.1 million. The company is facing liquidity challenges, including an unpaid $10 million clearance payment due to BioTissue and a substantial decrease in cash from $29.5 million to $971,145 over the nine-month period.

Key figure
Net loss $11.4M
4:06 PM ET 8-K
Financial Results

BioStem Technologies Financial Results

BioStem Technologies reported Q3 2026 financial results, highlighting sequential hospital revenue growth to $6.8 million and increased customer penetration. The company raised its full-year 2026 revenue guidance and is finalizing a cost reduction plan to reduce annualized cash operating expenses by $10-$12 million.

Term
Q3 2026

“We grew hospital revenue again this quarter, and importantly, are doing so by adding new accounts and increasing penetration with existing customers. The number of customers buying two or more of our product lines grew 14% from the second quarter. We also completed the final step of our commercial infrastructure build-out, and with in-house production of Neox and Clarix expected to begin in the first half of 2027, we are on track to become a fully vertically integrated company with those product lines.”

Jason Matuszewski, Chair and CEO of BioStem

“With these foundations in place, we are focused on strengthening the balance sheet, raising our gross margin, reducing operating expenses and narrowing our adjusted EBITDA loss as we work toward breakeven.”

Jason Matuszewski, Chair and CEO of BioStem
4:49 PM ET 8-K
Capital Raise

BioStem Technologies Capital Raise of $3M

BioStem Technologies entered into a securities purchase agreement with institutional investors for a $3.0 million private placement of 735,296 shares of common stock. The offering includes Series A and Series B warrants to purchase additional shares at an exercise price of $3.83 per share, which could provide an additional $5.6 million if fully exercised. Proceeds are intended for working capital and general corporate purposes.

Value
$3M
Counterparty
institutional investors
4:16 PM ET 8-K
Other 8-K Filing

BioStem Technologies Other 8-K Filing

BioStem Technologies entered into a $40 million committed equity facility with Roth Principal Investments, allowing the company to sell shares of common stock at its discretion over a 36-month period. The facility provides opportunistic access to capital for working capital and general corporate purposes, though no shares were sold at the time of the filing. Sales are subject to a registration statement being declared effective and a minimum threshold price of $1.00 per share.

Counterparty
Roth Principal Investments, LLC
Term
36 months

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.